Synthesis and hypoxia selective radiosensitization potential of β-2-FAZA and β-3-FAZL: Fluorinated azomycin β-nucleosides

Medicinal Chemistry

Volumn 5, Issue 2, 2009, Pages 118-129

  Kumar, P ^a   Emami, S ^b,c   Kresolek, Z ^a   Yang, J ^a   McEwan, A J B ^a   Wiebe, L I ^a,b  

^a CROSS CANCER INSTITUTE   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

analogs; Azomycin nucleosides; Cancer; FAZA; Radiosensitization; Tissue hypoxia

Indexed keywords

1 BETA DEXTRO (2 DEOXY 2 FLUOROARABINOFURANOSYL) 2 NITROIMIDAZOLE; 1 BETA DEXTRO (3 DEOXY 2 FLUOROLYXOFURANOSYL) 2 NITROIMIDAZOLE; 2 NITROIMIDAZOLE; FLUOROAZOMYCIN ARABINOSIDE; FLUORODEOXYGLUCOSE F 18; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG; FLUORINE; NITROIMIDAZOLE DERIVATIVE; NUCLEOSIDE;

ARTICLE; CELL STRAIN HCT116; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG LABELING; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; FLUORINATION; HUMAN; HUMAN CELL; HYPOXIA; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RADIOSENSITIZATION; CHEMICAL STRUCTURE; CHEMISTRY; HYDROPHOBICITY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RADIATION DOSE; SYNTHESIS;

FLUORINE RADIOISOTOPES; HCT116 CELLS; HUMANS; HYDROPHOBICITY; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; NITROIMIDAZOLES; NUCLEOSIDES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS;

EID: 65349109196     PISSN: 15734064     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340609787582945     Document Type: Article

References (40)

1. Koch, C.J.; Evans, S.M: Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labelled 2-nitroimidazoles. Adv. Exp. Med. Biol., 2003, 510, 285-92.
2. Koh, W.J.; Bergman, K.S.; Rasey, J.S.; Peterson, L.M.; Evans, M.L.; Graham, M.M.; Grierson, J.R.; Lindsley, K.L.; Lewellen, T.K.; Krohn. K.A.; Griffin, T.W: Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys., 1995, 33, 391-98.
3. Hockel, M.; Schlenger, K.; Aral, B.; Mitze, M.; Schaffer, U.; Vaupel, P: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res., 1996, 56, 4509-15.
4. Molls, M.; Feldmann, H.J.; Fuller, J: Oxygenation of locally advanced recurrent rectal cancer, soft tissue sarcoma and breast cancer. Adv. Exp. Med. Biol., 1994, 345, 459-63.
5. Molls, M.; Stadler, P.; Becker, A.; Feldmann, H.J.; Dunst, J: Relevance of oxygen in radiation oncology. Mechanisms of action, correlation to low hemoglobin levels. Strahlenther. Onkol., 1998, 174 (suppl 4), 13-6.
6. Harrison, L.B.; Chadha, M.; Hill, R.J.; Hu, K.; Shasha, D: Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist, 2002, 7, 492-508.
7. Brizel, D.M.; Dodge, R.K.; Clough, R.W.; Dewhirst, M.W: Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother. Oncol., 1999, 53, 113-17.
8. Bottaro, D.P.; Liotta, L.A: Cancer: Out of air is not out of action. Nature, 2003, 423, 593-95.
9. Pennacchietti, S.; Michieli, P.; Galluzzo, M.; Mazzone, M.; Giordano, S.; Comoglio, P.M: Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell., 2003, 3, 347-61.
10. Denny, W.A: Prodrug strategies in cancer therapy. Eur. J. Med. Chem., 2001, 36, 577-95.
11. Brown, J.M.; Workman, P: Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat. Res., 1980, 82, 171-90.
12. Adams, G.E.; Cooke, M.S: Electron-affinic sensitization. I. A structural basis for chemical radiosensitizers in bacteria. Int. J. Radial. Biol. Relat. Stud. Phys. Chem. Med., 1969, 15, 457-71.
13. Weissleder, R.; Mahmood, U: Molecular imaging. Radiology, 2001, 219, 316-33.
14. McNeil, T.H.; Koek, L.L.; Brown, S.A.; Hamill, R.W.; Wu, J.Y: Effect of misonidazole on neurotransmitter systems. Int. J. Radiat. Oncol. Biol. Phys., 1986, 12, 1067-70.
15. Koh, W.J.; Rasey, J.S.; Evans, M.L.; Grierson J.R.; Lewellen, T.K.; Graham, M.M.; Krohn, K.A.; Griffin, T.W: Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int. J. Radiat. Oncol. Biol. Phys., 1992, 22, 199-212.
16. Caldwell, J.H.; Revenaugh, J.R.; Martin, G.V.; Johnson, P.M.; Rasey, J.S.; Krohn, K.A: Comparison of fluorine-18-fluorodeoxyglucose and tritiated fluoromisonidazole uptake during low-flow ischemia. J. Nucl. Med., 1995, 36, 1633-38.
17. Piert, M.; Machulla, H.; Becker, G.; Stahlschmidt, A.; Patt, M.; Dibmann, P.D.; Fischer, H.; Becker, H.D.; Lauchart, W: Introducing fluorine-18 fluoromisonidazole positron emission tomography for the localisation and quantification of pig liver hypoxia. Eur. J. Nucl. Med., 1999, 26, 95-109.
18. Piert, M.; Machulla, H.J.; Becker, G.; Aldinger, P.; Winter, E.; Bares, R: Dependency of the [18F]fluoromisonidazole uptake on oxygen delivery and tissue oxygenation in the porcine liver. Nucl. Med. Biol., 2000, 27, 693-700.
19. Evans, S.M.; Kachur, A.V.; Shiue, C-Y.; Hustinx, R.; Jenkins, W.T.; Shive, G.G.; Karp, J.S.; Alavi, A.; Lord, E.M.; Dolbier, W.R. Jr.; Koch, C.J: Noninvasive detection of tumor hypoxia using the 2-nitroimidazoles. J. Nucl. Med., 2000, 41, 327-36.
20. 18F]FETNIM: a potential marker for PET. J. Nucl. Med., 2001, 42, 1397-404.
21. 3H-labelling and preliminary biological evaluation of a novel 2-nitroimidazole marker of tissue hypoxia. J. Labelled Comp. Radiopharm., 1999, 42, 3-16.
22. Piert, M.; Machulla, H-J.; Picchio, M.; Reischl, G.; Zeigler, S.; Kumar, P.; Wiebe, L.I.; Schwaiger, M: Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J. Nucl. Med., 2005, 46, 106-13.
23. Reischl, G.; Ehrlichmann, W.; Bieg, C.; Kumar, P.; Wiebe, L.I.; Machulla, H-J: Preparation of the hypoxia imaging PET tracer [18F]FAZA: reaction parameters and automation. Appl. Radiat. Isot., 2005, 62, 897-901.
24. Beck, R.; Röper, B.; Carlsen, J.M.; Huisman, M.C.; Lebschi, J.A.; Andratschke, N.; Picchio, M.; Souvatzoglou, M.; Machulla, H-J.; Piert, M: Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J. Nucl. Med., 2007, 486, 973-80.
25. http://clinicaltrials.gov/ct/show/NCT00388687. Medical University of Vienna, Austria. 2006.
26. Souvatzoglou, M.; Grosu, A.; Röper, B.; Krause, B.; Beck, R.; Reischl, G.; Picchio, M.; Machulla, H.-J.; Wester, H.-J.; Piert, M: Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study. Eur. J. Nucl. Med. Mol. Imaging., 2007, 34(10), 1566-75.
27. http://clinicaltrials.gov/ct/show/NCT00323076. Cross Cancer Institute, Edmonton, Canada. 2007.
28. Sorger, D.; Patt, M.; Kumar, P.; Wiebe, L.I.; Barthel, H.; Seese, A.; Dannenberg, C.; Tannapfel, A.; Osama Sabri, R.K: [18F]Fluoro-azomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl. Med. Biol., 2003, 30, 317-26.
29. 18F]MISO. J. Labelled Compd. Radiopharm., 2007, 50 (S1), S429.
30. Reischl, G.; Hammerschmidt, F.; Woschek, A.; Lamparter, D.; Kneilling, M.; Maier, F; Pichler, B.J.; Machulla, H.-J: 17th International Symposium on Radiopharmaceutical Chemistry, Aachen, Germany 27th March-4th April 2007.
31. 18F]FAZA. J. Nucl. Med., 2007, 48: 292P.
32. Emami, S.; Kumar, P.; Yang, J.; Kresolic, Z.; Paproski, R.; Cass, C.; McEwan, A.J.B.; Wiebe, L.I: Synthesis, transportability and hypoxia selective binding of 1-β-D-(5-Deoxy-5-fluororibofuranosyl)-2-nitroimidazole (β-5-FAZR), a configurational isomer of the clinical hypoxia marker, FAZA. J. Pharm. Pharm. Sci., 2007, 10, 237-45.
33. Kumar, P.; Wiebe, L.I.; Beiki, D.; Ohkura, K.; Seki, K-I: 2′-Iodo-β-azomycin arabinofuranoside (β-2-IAZA): Search for potential markers of tissue hypoxia among β-azomycin nucleosides. Tetrahaderon Lett., 2002, 43, 4427-29.
34. Neumann, H.; Shashoua, V.E.; Sheehan, J.C.; Rich, A: Intramolecular acyl migration in adenosine derivatives. Proc. Nat. Acad. Sci. USA, 1968, 61, 1207-14.
35. Van der Kelen, G.P.; Eeckhaut, Z: C13 Splittings in proton and fluorine nuclear magnetic resonance spectra of halogenated aliphatic compounds. J. Mol. Spectrosc., 1963, 10, 141.
36. Mannan, R.H. Radioiodinated sugar-coupled 2-nitroimidazoles: Novel non-invasive markers of hypoxic tumor tissue. Ph.D. Thesis, University of Alberta, 1991.
37. Biskupiak, J.E.; Grierson, J.R.; Rasey, J.S.; Martin, G.V.; Krohn, K.A: Synthesis of an (iodovinyl)misonidazole derivative for hypoxia imaging. J. Med. Chem., 1991, 34, 2165-68.
38. Brown, J.M.; Lemmon, M.J: SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes. Radiother. Oncol., 1991, 20, 151-6.
39. Dischino, D.D.; Welch, M.J.; Kilbourn, M.R.; Raichle, M.E: Relationship between lipophilicity and brain extraction of C-11 labeled radiopharmaceuticals. J. Nucl. Med., 1983, 24, 1030-38.
40. Braasch, D.A.; Jensen, S.; Liu, Y.; Kaur, K.; Arar, K.; White, M.A.; Corey, D.R: RNA interference in mammalian cells by chemically-modified RNA. Biochemistry, 2003, 42, 7967-75.